Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040

Incannex Healthcare Inc.

USPTO granted patent for IHL-42X composition and methods for OSA; baseline expiry 9 July 2040.
Company exploring patent term extension after potential FDA approval to lengthen exclusivity.
IHL-42X has FDA Fast Track designation, positive Phase II data; DReAMzz study nearing patient recruitment with site IRB approvals and DEA registrations.
CEO states patent validates IHL-42X as differentiated asset targeting billion-person OSA market with poor adherence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.